<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247350</url>
  </required_header>
  <id_info>
    <org_study_id>14089</org_study_id>
    <secondary_id>I4V-JE-JADM</secondary_id>
    <nct_id>NCT01247350</nct_id>
  </id_info>
  <brief_title>A Study of LY3009104(Baricitinib) for Healthy Subjects</brief_title>
  <official_title>A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Japanese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of LY3009104 when given orally as single and multiple
      doses in Japanese healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Effects</measure>
    <time_frame>Days 1-10 for Cohorts 1 &amp; 2, Days 1-7 for single dose of Cohorts 3 &amp; 4, Days 8-31 for multiple doses</time_frame>
    <description>Adverse events were considered clinically significant effects. A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104</measure>
    <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
    <description>Cmax of Day 1 is Cmax after single dose, and Cmax of Day 17 is Cmax at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104</measure>
    <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
    <description>AUC is the measure of total plasma exposure of a drug over a given time period. AUC of Day 1 is AUC from 0 to 24 hours. AUC of Day 17 is AUC during one dosing interval at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Half-Life(t1/2) of LY3009104</measure>
    <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
    <description>Half life (t1/2) is the time measured for the plasma concentration of LY3009104 to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent Volume of Distribution of LY3009104</measure>
    <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
    <description>Apparent volume of distribution is used to quantify the distribution of a drug between plasma and the rest of the body after dosing. It is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Day 1, it is apparent volume of distribution during the terminal phase after single dose. Day 17, it is apparent volume of distribution during the terminal phase at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent Total Body Clearance of LY3009104</measure>
    <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose</time_frame>
    <description>Apparent total body clearance is the volume of plasma from which the drug is completely removed in a given time period. For Day 1, it is apparent total body clearance of drug after single dose. For Day 17, it is apparent total body clearance of drug at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)</measure>
    <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose</time_frame>
    <description>Tmax is time to reach maximum observed drug concentration. For Day 1, it is tmax after single dose. For Day 17, it is tmax at steady-state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Renal Excretion of LY3009104</measure>
    <time_frame>Day 1: continuous for 24 hours</time_frame>
    <description>Percentage of LY3009104 excreted in urine from zero to 24 hours.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>2 mg LY3009104 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg administered once on day 1 (single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg LY3009104 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg administered once on day 1 (single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg LY3009104 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14 mg LY3009104 (Cohort 4 )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3009104</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>2 mg LY3009104 (Cohort 1)</arm_group_label>
    <arm_group_label>5 mg LY3009104 (Cohort 2)</arm_group_label>
    <arm_group_label>10 mg LY3009104 (Cohort 3)</arm_group_label>
    <arm_group_label>14 mg LY3009104 (Cohort 4 )</arm_group_label>
    <other_name>baricitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females. Male subjects: Agree to use 2 forms of highly effective
             methods of birth control with female partners of childbearing potential for the
             specified duration. Female subjects: Females must not be pregnant, breastfeeding, or
             at risk to become pregnant during study participation. Female subjects of childbearing
             potential must test negative for pregnancy at screening and agree to use 2 forms of
             highly effective methods of birth control, or remain abstinent for the specified
             duration.

          -  Up to third generation Japanese, that is defined as all of the subject's biological
             grandparents are of exclusive Japanese decent and have been born in Japan.

          -  Are between the body mass index (BMI) of 18.0 and 30.0 kg/mÂ², inclusive at screening.

        Exclusion Criteria:

          -  Are subjects who have previously completed or withdrawn from this study or any other
             study investigating LY3009104, and received the study drug.

          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data.

          -  Show evidence of significant active neuropsychiatric disease.

          -  Have current or recent history of herpes zoster or simplex in the last 90 days prior
             to randomization, or history of herpes zoster, such as disseminated herpes zoster
             involving multiple dermatomes, ocular involvement, including herpes zoster involving
             the ophthalmic branch of the trigeminal nerve.

          -  Have or have a history of rheumatoid arthritis.

          -  History of malignancy, with the exception of cured basal cell or squamous cell
             carcinoma of the skin.

          -  History of stomach or intestinal surgery, except that appendectomy and/or
             cholecystectomy will be allowed.

          -  Receipt of blood products within 2 months prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>September 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2 mg LY3009104 (Baricitinib)</title>
          <description>2 mg administered orally once on Day 1 (single dose)</description>
        </group>
        <group group_id="P2">
          <title>5 mg LY3009104</title>
          <description>5 mg administered orally once on Day 1 (single dose)</description>
        </group>
        <group group_id="P3">
          <title>10 mg LY3009104</title>
          <description>10 mg administered orally on Day 1 (single dose) and following a 7-day washout period, administered once daily for 10 days ((multiple dose)</description>
        </group>
        <group group_id="P4">
          <title>14 mg LY3009104</title>
          <description>14 mg administered orally on Day 1 (single dose) and following a 7-day washout period, administered once daily for 10 days (multiple dose)</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>administered orally on Day 1 (single dose) and following a 7-day washout period, administered once daily for 10 days (multiple dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Multiple Doses of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2 mg LY3009104</title>
          <description>2 mg administered orally once on Day 1 (single dose)</description>
        </group>
        <group group_id="B2">
          <title>5 mg LY3009104</title>
          <description>5 mg administered orally once on Day 1 (single dose)</description>
        </group>
        <group group_id="B3">
          <title>10 mg LY3009104</title>
          <description>10 mg administered orally on Day 1 (single dose) and following a 7-day washout period, administered once daily for 10 days ((multiple dose)</description>
        </group>
        <group group_id="B4">
          <title>14 mg LY3009104</title>
          <description>14 mg administered orally on Day 1 (single dose) and following a 7-day washout period, administered once daily for 10 days (multiple dose)</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>administered orally on Day 1 (single dose) and following a 7-day washout period, administered once daily for 10 days (multiple dose)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="10.8"/>
                    <measurement group_id="B2" value="48.0" spread="15.0"/>
                    <measurement group_id="B3" value="46.7" spread="9.0"/>
                    <measurement group_id="B4" value="51.1" spread="6.3"/>
                    <measurement group_id="B5" value="45.1" spread="10.7"/>
                    <measurement group_id="B6" value="47.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Effects</title>
        <description>Adverse events were considered clinically significant effects. A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.</description>
        <time_frame>Days 1-10 for Cohorts 1 &amp; 2, Days 1-7 for single dose of Cohorts 3 &amp; 4, Days 8-31 for multiple doses</time_frame>
        <population>Participants who were administered study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg LY3009104 Single Dose</title>
            <description>2 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY3009104 Single Dose</title>
            <description>5 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY3009104 Single Dose</title>
            <description>10 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O4">
            <title>14 mg LY3009104 Single Dose</title>
            <description>14 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo Single Dose</title>
            <description>administered orally once on Day 1</description>
          </group>
          <group group_id="O6">
            <title>10 mg LY3009104 Multiple Dose</title>
            <description>Following a 7-day washout period, participants in the 10 mg LY3009104 single-dose group received 10 mg LY3009104 once daily for 10 days</description>
          </group>
          <group group_id="O7">
            <title>14 mg LY3009104 Multiple Dose</title>
            <description>Following a 7-day washout period, participants in the 14 mg LY3009104 single-dose group received 14 mg LY3009104 once daily for 10 days</description>
          </group>
          <group group_id="O8">
            <title>Placebo Multiple Dose</title>
            <description>Following a 7-day washout period, participants in the placebo single-dose group received placebo once daily for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Effects</title>
          <description>Adverse events were considered clinically significant effects. A summary of serious adverse events and other nonserious adverse events are located in the Reported Adverse Event section.</description>
          <population>Participants who were administered study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonserious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104</title>
        <description>Cmax of Day 1 is Cmax after single dose, and Cmax of Day 17 is Cmax at steady-state.</description>
        <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
        <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg LY3009104 Day 1</title>
            <description>2 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY3009104 Day 1</title>
            <description>5 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY3009104 Day 1</title>
            <description>10 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O4">
            <title>14 mg LY3009104 Day 1</title>
            <description>14 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 10 mg LY3009104 single-dose group received 10 mg LY3009104 once daily for 10 days</description>
          </group>
          <group group_id="O6">
            <title>14 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 14 mg LY3009104 single-dose group received 14 mg LY3009104 once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY3009104</title>
          <description>Cmax of Day 1 is Cmax after single dose, and Cmax of Day 17 is Cmax at steady-state.</description>
          <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
          <units>nanomoles/Liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="29"/>
                    <measurement group_id="O2" value="220" spread="35"/>
                    <measurement group_id="O3" value="327" spread="43"/>
                    <measurement group_id="O4" value="410" spread="19"/>
                    <measurement group_id="O5" value="319" spread="30"/>
                    <measurement group_id="O6" value="439" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104</title>
        <description>AUC is the measure of total plasma exposure of a drug over a given time period. AUC of Day 1 is AUC from 0 to 24 hours. AUC of Day 17 is AUC during one dosing interval at steady-state.</description>
        <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
        <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg LY3009104 Day 1</title>
            <description>2 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY3009104 Day 1</title>
            <description>5 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY3009104 Day 1</title>
            <description>10 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O4">
            <title>14 mg LY3009104 Day 1</title>
            <description>14 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 10 mg LY3009104 single-dose group received 10 mg LY3009104 once daily for 10 days</description>
          </group>
          <group group_id="O6">
            <title>14 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 14 mg LY3009104 single-dose group received 14 mg LY3009104 once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3009104</title>
          <description>AUC is the measure of total plasma exposure of a drug over a given time period. AUC of Day 1 is AUC from 0 to 24 hours. AUC of Day 17 is AUC during one dosing interval at steady-state.</description>
          <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
          <units>nanomoles*hour/Liter (nmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403" spread="10"/>
                    <measurement group_id="O2" value="1240" spread="23"/>
                    <measurement group_id="O3" value="1730" spread="21"/>
                    <measurement group_id="O4" value="2790" spread="14"/>
                    <measurement group_id="O5" value="1970" spread="18"/>
                    <measurement group_id="O6" value="3060" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Half-Life(t1/2) of LY3009104</title>
        <description>Half life (t1/2) is the time measured for the plasma concentration of LY3009104 to decrease by one half.</description>
        <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
        <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg LY3009104 Day 1</title>
            <description>2 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY3009104 Day 1</title>
            <description>5 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY3009104 Day 1</title>
            <description>10 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O4">
            <title>14 mg LY3009104 Day 1</title>
            <description>14 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 10 mg LY3009104 single-dose group received 10 mg LY3009104 once daily for 10 days</description>
          </group>
          <group group_id="O6">
            <title>14 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 14 mg LY3009104 single-dose group received 14 mg LY3009104 once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Half-Life(t1/2) of LY3009104</title>
          <description>Half life (t1/2) is the time measured for the plasma concentration of LY3009104 to decrease by one half.</description>
          <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
          <units>hour (h)</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" lower_limit="3.88" upper_limit="6.31"/>
                    <measurement group_id="O2" value="6.82" lower_limit="5.70" upper_limit="7.79"/>
                    <measurement group_id="O3" value="6.43" lower_limit="4.37" upper_limit="9.90"/>
                    <measurement group_id="O4" value="8.48" lower_limit="6.95" upper_limit="10.8"/>
                    <measurement group_id="O5" value="8.57" lower_limit="7.43" upper_limit="9.30"/>
                    <measurement group_id="O6" value="9.41" lower_limit="7.24" upper_limit="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Apparent Volume of Distribution of LY3009104</title>
        <description>Apparent volume of distribution is used to quantify the distribution of a drug between plasma and the rest of the body after dosing. It is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Day 1, it is apparent volume of distribution during the terminal phase after single dose. Day 17, it is apparent volume of distribution during the terminal phase at steady-state.</description>
        <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hours postdose</time_frame>
        <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg LY3009104 Day 1</title>
            <description>2 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY3009104 Day 1</title>
            <description>5 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY3009104 Day 1</title>
            <description>10 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O4">
            <title>14 mg LY3009104 Day 1</title>
            <description>14 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 10 mg LY3009104 single-dose group received 10 mg LY3009104 once daily for 10 days</description>
          </group>
          <group group_id="O6">
            <title>14 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 14 mg LY3009104 single-dose group received 14 mg LY3009104 once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Apparent Volume of Distribution of LY3009104</title>
          <description>Apparent volume of distribution is used to quantify the distribution of a drug between plasma and the rest of the body after dosing. It is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Day 1, it is apparent volume of distribution during the terminal phase after single dose. Day 17, it is apparent volume of distribution during the terminal phase at steady-state.</description>
          <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
          <units>Liter (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" spread="18"/>
                    <measurement group_id="O2" value="99.4" spread="29"/>
                    <measurement group_id="O3" value="138" spread="41"/>
                    <measurement group_id="O4" value="150" spread="19"/>
                    <measurement group_id="O5" value="169" spread="24"/>
                    <measurement group_id="O6" value="167" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Apparent Total Body Clearance of LY3009104</title>
        <description>Apparent total body clearance is the volume of plasma from which the drug is completely removed in a given time period. For Day 1, it is apparent total body clearance of drug after single dose. For Day 17, it is apparent total body clearance of drug at steady-state.</description>
        <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose</time_frame>
        <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg LY3009104 Day 1</title>
            <description>2 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY3009104 Day 1</title>
            <description>5 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY3009104 Day 1</title>
            <description>10 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O4">
            <title>14 mg LY3009104 Day 1</title>
            <description>14 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 10 mg LY3009104 single-dose group received 10 mg LY3009104 once daily for 10 days</description>
          </group>
          <group group_id="O6">
            <title>14 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 14 mg LY3009104 single-dose group received 14 mg LY3009104 once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Apparent Total Body Clearance of LY3009104</title>
          <description>Apparent total body clearance is the volume of plasma from which the drug is completely removed in a given time period. For Day 1, it is apparent total body clearance of drug after single dose. For Day 17, it is apparent total body clearance of drug at steady-state.</description>
          <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
          <units>Liter/hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="11"/>
                    <measurement group_id="O2" value="10.1" spread="22"/>
                    <measurement group_id="O3" value="14.8" spread="20"/>
                    <measurement group_id="O4" value="12.2" spread="17"/>
                    <measurement group_id="O5" value="13.7" spread="18"/>
                    <measurement group_id="O6" value="12.3" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)</title>
        <description>Tmax is time to reach maximum observed drug concentration. For Day 1, it is tmax after single dose. For Day 17, it is tmax at steady-state.</description>
        <time_frame>Day 1 and Day 17: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 38 and 48 hours postdose</time_frame>
        <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>2 mg LY3009104 Day 1</title>
            <description>2 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O2">
            <title>5 mg LY3009104 Day 1</title>
            <description>5 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O3">
            <title>10 mg LY3009104 Day 1</title>
            <description>10 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O4">
            <title>14 mg LY3009104 Day 1</title>
            <description>14 mg administered orally once on Day 1</description>
          </group>
          <group group_id="O5">
            <title>10 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 10 mg LY3009104 single-dose group received 10 mg LY3009104 once daily for 10 days</description>
          </group>
          <group group_id="O6">
            <title>14 mg LY3009104 Day 17</title>
            <description>Following a 7-day washout period, participants in the 14 mg LY3009104 single-dose group received 14 mg LY3009104 once daily for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time of Maximum Observed LY3009104 Concentration (Tmax)</title>
          <description>Tmax is time to reach maximum observed drug concentration. For Day 1, it is tmax after single dose. For Day 17, it is tmax at steady-state.</description>
          <population>Participants who were administered study drug and had pharmacokinetics (PK) samples for the analyses.</population>
          <units>hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.25" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.50" upper_limit="2.10"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Renal Excretion of LY3009104</title>
        <description>Percentage of LY3009104 excreted in urine from zero to 24 hours.</description>
        <time_frame>Day 1: continuous for 24 hours</time_frame>
        <population>Participants who were administered study drug (10 mg and 14 mg LY3009104 per protocol) and had pharmacokinetics (PK) samples for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg LY3009104 Day 1</title>
            <description>10 mg administered orally on Day 1</description>
          </group>
          <group group_id="O2">
            <title>14 mg LY3009104 Day 1</title>
            <description>14 mg administered orally on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Renal Excretion of LY3009104</title>
          <description>Percentage of LY3009104 excreted in urine from zero to 24 hours.</description>
          <population>Participants who were administered study drug (10 mg and 14 mg LY3009104 per protocol) and had pharmacokinetics (PK) samples for the analyses.</population>
          <units>percentage of drug</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="7"/>
                    <measurement group_id="O2" value="63.6" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From starting of the dose to follow-up. Adverse events (AE) for single dose were observed from Day 1 to Day 10Â±2 days (Cohorts 1&amp;2) or Day 7 (Cohorts 3&amp;4). AE for multiple doses were observed from Day 8 to Day 31Â±3 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2 mg LY3009104 - Single Dose</title>
          <description>2 mg administered orally once on Day 1</description>
        </group>
        <group group_id="E2">
          <title>5 mg LY3009104 - Single Dose</title>
          <description>5 mg administered orally once on Day 1</description>
        </group>
        <group group_id="E3">
          <title>10 mg LY3009104 - Single Dose</title>
          <description>10 mg administered orally on Day 1</description>
        </group>
        <group group_id="E4">
          <title>14 mg LY3009104 - Single Dose</title>
          <description>14 mg administered orally on Day 1</description>
        </group>
        <group group_id="E5">
          <title>Placebo - Single Dose</title>
          <description>administered orally on Day 1</description>
        </group>
        <group group_id="E6">
          <title>10 mg LY3009104 - Multiple Dose</title>
          <description>Following a 7-day washout period, participants in the 10 mg LY3009104 single-dose group received 10 mg LY3009104 once daily for 10 days</description>
        </group>
        <group group_id="E7">
          <title>14 mg LY3009104 - Multiple Dose</title>
          <description>Following a 7-day washout period, participants in the 14 mg LY3009104 single-dose group received 14 mg LY3009104 once daily for 10 days</description>
        </group>
        <group group_id="E8">
          <title>Placebo - Multiple Dose</title>
          <description>Following a 7-day washout period, participants in the placebo single-dose group received placebo once daily for 10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Reticulocyte Count Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

